Nkarta is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
NKX019 Clinical Update Presentation - December 2022
NKX101 and NKX019 Initial Clinical Data Presentation – April 2022
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Jan 09, 2023
Dec 05, 2022
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Dec 02, 2022